Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

INSIDE INFORMATION ANNOUNCEMENT GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR IMPLEMENTATION OF THE H SHARE FULL CIRCULATION

This announcement is made by TransThera Sciences (Nanjing), Inc. (藥捷安康(南京)科技股份有限公司) (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated (i) October 20, 2025 in relation to the proposed implementation of the H share full circulation by the Company; and (ii) October 26, 2026 in relation to the issuance of the filing notice by the China Securities Regulatory Commission for the H share full circulation of the Company (collectively, the "**Announcements**"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

LISTING APPROVAL BY THE STOCK EXCHANGE

The Board is pleased to announce that the Stock Exchange has granted approval (the "**Listing Approval**") for the listing of, and permission to deal in (the "**Listing**"), 44,971,128 H Shares (the "**Converted H Shares**") to be converted from 44,971,128 Unlisted Shares (the "**Conversion**") held by 10 shareholders of the Company (the "**Participating Shareholders**"). The Listing Approval was granted by the Stock Exchange on October 30, 2026.

SHAREHOLDING STRUCTURE

The Conversion and the Listing will involve 44,971,128 Unlisted Shares held by the 10 Participating Shareholders, representing approximately 11.01 % of the total issued share capital of the Company as at the date of this announcement. Details of the Participating Shareholders and their respective Unlisted Shares to be converted into H Shares are set out below:

Name of Participating Shareholder	Number of Unlisted Shares to be converted into H Shares	Approximate percentage of the Company's total issued share capital
CPE Investment (Hong Kong) 2021 Limited	21,521,091	5.27%
Shanghai Guoxin Investment Development Co., Ltd. (上海國鑫投資發展有限公司)	8,314,088	2.03%
Nanjing Jiangbei Medical Innovation Industry Fund (Limited Partnership) (南京江北醫療創新產業基金(有限合夥))	3,810,122	0.93%
Nanjing Jiangbei New Area State-owned Assets Management Co., Ltd. (南京江北新區國有資產管理有限公司)	3,657,040	0.90%
Nanjing Enran Ruiguang Venture Capital Partnership (Limited Partnership) (南京恩然瑞光創業投資合夥企業(有限合夥))	1,668,893	0.41%
Taixing Qichen Emerging Industry Venture Capital Fund Partnership (Limited Partnership) (泰興市啟辰新興產業創業投資基金合夥企業(有限合夥))	1,662,818	0.41%
BOC Capital Investment Holdings Co., Ltd. (中銀資本投資控股有限公司)	1,662,818	0.41%
Nanjing Qirui Youkang Venture Capital Partnership (Limited Partnership) (南京其瑞佑康創業投資合夥企業(有限合夥))	1,011,440	0.25%
Jiangsu Sino-German Trade in Services Industry Investment Fund (Limited Partnership) (江蘇中德服貿產業投資基金(有限合夥))	831,409	0.20%
Nanjing Baiyide Equity Investment Partnership (Limited Partnership) (南京百益德股權投資合夥企業(有限合夥))	831,409	0.20%
Total	**44,971,128**	**11.01%**

Notes:

(1) The percentages have been rounded to two decimal places. Any discrepancies between the totals and the sums of the amounts listed in the table are due to rounding.

(2) The percentages are calculated based on a total of 408,578,633 Shares in issue as at the date of this announcement.

The share capital structure of the Company as at the date of this announcement and immediately upon completion of the Conversion and the Listing is set out below:

Class of shares	**As at the date of this announcement**		**Upon completion of the Conversion and the Listing**	
	Number of shares	*Approximate percentage %*	*Number of shares*	*Approximate percentage %*
H shares	313,347,673	76.69%	358,318,801	87.70%
Unlisted shares	95,230,960	23.31%	50,259,832	12.30%
Total	408,578,633	100.00%	408,578,633	100.00%

Note: The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

The Company will complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and the Listing in accordance with the Listing Rules and applicable laws, as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, November 1, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Ms. Chui Hoi Yam, Mr. Feng Weibo and Mr. Li Shu Pai as independent non-executive directors.